Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picato and MAL PDT for Actinic Keratosis
NCT02354391Phase 2Unknown
- Sponsor
- Pacific Dermaesthetics
- Start
- Jan 2015
- Primary completion
- Dec 2019
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ingenol mebutate in actinic keratosis (AK), sponsored by Pacific Dermaesthetics. Primary endpoint: Complete clearance of lesions at 60 days. Status: unknown.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02354391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354391.